[go: up one dir, main page]

AU2001220765A1 - Mixed buffer system for stabilizing polypeptide formulations - Google Patents

Mixed buffer system for stabilizing polypeptide formulations

Info

Publication number
AU2001220765A1
AU2001220765A1 AU2001220765A AU2076501A AU2001220765A1 AU 2001220765 A1 AU2001220765 A1 AU 2001220765A1 AU 2001220765 A AU2001220765 A AU 2001220765A AU 2076501 A AU2076501 A AU 2076501A AU 2001220765 A1 AU2001220765 A1 AU 2001220765A1
Authority
AU
Australia
Prior art keywords
buffer system
mixed buffer
polypeptide formulations
stabilizing polypeptide
stabilizing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001220765A
Inventor
Poonam S. Gulati
William Peter Van Antwerp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medtronic Minimed Inc
Original Assignee
Minimed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minimed Inc filed Critical Minimed Inc
Publication of AU2001220765A1 publication Critical patent/AU2001220765A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001220765A 2000-01-24 2000-12-08 Mixed buffer system for stabilizing polypeptide formulations Abandoned AU2001220765A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17789700P 2000-01-24 2000-01-24
US60177897 2000-01-24
PCT/US2000/033358 WO2001052937A1 (en) 2000-01-24 2000-12-08 Mixed buffer system for stabilizing polypeptide formulations

Publications (1)

Publication Number Publication Date
AU2001220765A1 true AU2001220765A1 (en) 2001-07-31

Family

ID=22650368

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001220765A Abandoned AU2001220765A1 (en) 2000-01-24 2000-12-08 Mixed buffer system for stabilizing polypeptide formulations

Country Status (3)

Country Link
US (1) US6734162B2 (en)
AU (1) AU2001220765A1 (en)
WO (1) WO2001052937A1 (en)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9066695B2 (en) 1998-04-30 2015-06-30 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8974386B2 (en) 1998-04-30 2015-03-10 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6949816B2 (en) 2003-04-21 2005-09-27 Motorola, Inc. Semiconductor component having first surface area for electrically coupling to a semiconductor chip and second surface area for electrically coupling to a substrate, and method of manufacturing same
US8688188B2 (en) 1998-04-30 2014-04-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8465425B2 (en) 1998-04-30 2013-06-18 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6175752B1 (en) 1998-04-30 2001-01-16 Therasense, Inc. Analyte monitoring device and methods of use
US8346337B2 (en) 1998-04-30 2013-01-01 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US8480580B2 (en) 1998-04-30 2013-07-09 Abbott Diabetes Care Inc. Analyte monitoring device and methods of use
US6560471B1 (en) 2001-01-02 2003-05-06 Therasense, Inc. Analyte monitoring device and methods of use
DE10114178A1 (en) * 2001-03-23 2002-10-10 Aventis Pharma Gmbh Zinc-free and low-zinc insulin preparations with improved stability
WO2002078512A2 (en) 2001-04-02 2002-10-10 Therasense, Inc. Blood glucose tracking apparatus and methods
US6737401B2 (en) 2001-06-28 2004-05-18 Metronic Minimed, Inc. Methods of evaluating protein formulation stability and surfactant-stabilized insulin formulations derived therefrom
DK1412384T3 (en) 2001-06-28 2008-04-28 Novo Nordisk As Stable formulation of modified GLP-1
DE10227232A1 (en) 2002-06-18 2004-01-15 Aventis Pharma Deutschland Gmbh Sour insulin preparations with improved stability
ITMI20021684A1 (en) * 2002-07-29 2004-01-29 Therapicon Srl PHARMACEUTICAL COMPOSITION OF NASAL PEPTIDE
US20090035260A1 (en) * 2002-07-29 2009-02-05 Therapicon Srl Enhanced nasal composition of active peptide
EP1578262A4 (en) 2002-12-31 2007-12-05 Therasense Inc Continuous glucose monitoring system and methods of use
AU2004232858B2 (en) 2003-04-23 2009-07-09 Mannkind Corporation Hydraulically actuated pump for long duration medicament administration
JP2007524592A (en) 2003-06-03 2007-08-30 ノボ・ノルデイスク・エー／エス Stabilized pharmaceutical peptide composition
KR101308912B1 (en) 2003-06-03 2013-09-23 노보 노르디스크 에이/에스 Stabilized pharmaceutical peptide compositions
US8066639B2 (en) 2003-06-10 2011-11-29 Abbott Diabetes Care Inc. Glucose measuring device for use in personal area network
CN113304250A (en) 2003-11-20 2021-08-27 诺和诺德股份有限公司 Propylene glycol-containing peptide formulations optimized for production and use in injection devices
ITMI20040235A1 (en) * 2004-02-13 2004-05-13 Therapicon Srl PHARMACEUTICAL PREPARATION FOR THE ORAL CABLE
EP1718198A4 (en) 2004-02-17 2008-06-04 Therasense Inc Method and system for providing data communication in continuous glucose monitoring and management system
US9089636B2 (en) 2004-07-02 2015-07-28 Valeritas, Inc. Methods and devices for delivering GLP-1 and uses thereof
CN103223160B (en) 2004-07-19 2015-02-18 比奥孔有限公司 Cation complexes of insulin compund conjugates, formulation and uses thereof
ES2442223T3 (en) 2004-08-31 2014-02-10 Novo Nordisk A/S Use of tris (hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
ES2735533T3 (en) 2004-11-12 2019-12-19 Novo Nordisk As GLP-1 stable formulations
CN101106979A (en) * 2005-01-21 2008-01-16 阿尔扎公司 Therapeutic peptide formulations for coating microneedles with improved stability containing at least one counterion
US8112240B2 (en) 2005-04-29 2012-02-07 Abbott Diabetes Care Inc. Method and apparatus for providing leak detection in data monitoring and management systems
EP1888117A1 (en) * 2005-05-25 2008-02-20 Novo Nordisk A/S Stabilized polypeptide formulations
WO2006125763A1 (en) * 2005-05-25 2006-11-30 Novo Nordisk A/S Stabilized polypeptide formulations
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
US7766829B2 (en) 2005-11-04 2010-08-03 Abbott Diabetes Care Inc. Method and system for providing basal profile modification in analyte monitoring and management systems
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
AU2007233231B2 (en) 2006-03-30 2011-02-24 Mannkind Corporation Multi-cartridge fluid delivery device
US7620438B2 (en) 2006-03-31 2009-11-17 Abbott Diabetes Care Inc. Method and system for powering an electronic device
US8226891B2 (en) 2006-03-31 2012-07-24 Abbott Diabetes Care Inc. Analyte monitoring devices and methods therefor
US20080071157A1 (en) 2006-06-07 2008-03-20 Abbott Diabetes Care, Inc. Analyte monitoring system and method
GB0700523D0 (en) * 2007-01-11 2007-02-21 Insense Ltd The Stabilisation Of Proteins
US8732188B2 (en) 2007-02-18 2014-05-20 Abbott Diabetes Care Inc. Method and system for providing contextual based medication dosage determination
US8930203B2 (en) 2007-02-18 2015-01-06 Abbott Diabetes Care Inc. Multi-function analyte test device and methods therefor
US8123686B2 (en) 2007-03-01 2012-02-28 Abbott Diabetes Care Inc. Method and apparatus for providing rolling data in communication systems
US8456301B2 (en) 2007-05-08 2013-06-04 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US8665091B2 (en) 2007-05-08 2014-03-04 Abbott Diabetes Care Inc. Method and device for determining elapsed sensor life
US8461985B2 (en) 2007-05-08 2013-06-11 Abbott Diabetes Care Inc. Analyte monitoring system and methods
US7928850B2 (en) 2007-05-08 2011-04-19 Abbott Diabetes Care Inc. Analyte monitoring system and methods
JP5868594B2 (en) 2007-10-16 2016-02-24 バイオコン・リミテッドＢｉｏｃｏｎ Ｌｉｍｉｔｅｄ Orally administrable solid pharmaceutical composition and process thereof
ES2648196T3 (en) * 2008-02-07 2017-12-29 The University Of Washington Circumferential spray device
EP2910569B1 (en) 2008-03-18 2016-10-05 Novo Nordisk A/S Protease stabilized, acylated insulin analogues
TWI451876B (en) * 2008-06-13 2014-09-11 Lilly Co Eli Pegylated insulin lispro compounds
MX390359B (en) 2008-08-15 2025-03-20 Ironwood Pharmaceuticals Inc FORMULATIONS CONTAINING LINACLOTIDE FOR ORAL ADMINISTRATION
EP3228320B1 (en) 2008-10-17 2019-12-18 Sanofi-Aventis Deutschland GmbH Combination of an insulin and a glp-1 agonist
US8103456B2 (en) 2009-01-29 2012-01-24 Abbott Diabetes Care Inc. Method and device for early signal attenuation detection using blood glucose measurements
WO2010127050A1 (en) 2009-04-28 2010-11-04 Abbott Diabetes Care Inc. Error detection in critical repeating data in a wireless sensor system
US9184490B2 (en) 2009-05-29 2015-11-10 Abbott Diabetes Care Inc. Medical device antenna systems having external antenna configurations
EP2612677B1 (en) * 2009-06-26 2015-05-06 Novo Nordisk A/S Preparation comprising insulin, nicotinamide and arginine
WO2011014882A1 (en) 2009-07-31 2011-02-03 Medtronic, Inc. CONTINUOUS SUBCUTANEOUS ADMINISTRATION OF INTERFERON-α TO HEPATITIS C INFECTED PATIENTS
CA2770077A1 (en) 2009-08-06 2011-02-10 Ironwood Pharmaceuticals, Inc. Formulations comprising linaclotide
WO2011026148A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte monitoring system and methods for managing power and noise
WO2011026147A1 (en) 2009-08-31 2011-03-03 Abbott Diabetes Care Inc. Analyte signal processing device and methods
WO2011041469A1 (en) 2009-09-29 2011-04-07 Abbott Diabetes Care Inc. Method and apparatus for providing notification function in analyte monitoring systems
BR112012011403B8 (en) 2009-11-13 2021-05-25 Sanofi Aventis Deutschland liquid pharmaceutical composition comprising a glp-1 agonist and methionine and use thereof
CA2780460C (en) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition comprising a glp-1 agonist, an insulin and methionine
US20110152820A1 (en) * 2009-12-22 2011-06-23 Medtronic Minimed, Inc. Barrier coatings for fluids contacting medical devices
CA2790213A1 (en) 2010-02-17 2011-08-25 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
HRP20192207T1 (en) 2010-08-11 2020-02-21 Ironwood Pharmaceuticals, Inc. Stable formulations of linaclotide
EP2611458B1 (en) 2010-08-30 2016-09-21 Sanofi-Aventis Deutschland GmbH Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
CN103917265B (en) 2011-03-03 2017-02-15 英倍尔药业股份有限公司 Nasal drug delivery device
EP3851142A1 (en) 2011-05-09 2021-07-21 Impel NeuroPharma Inc. Nozzles for nasal drug delivery
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2776055B1 (en) 2011-08-17 2016-12-14 Ironwood Pharmaceuticals, Inc. Treatments for gastrointestinal disorders
ES2550357T3 (en) 2011-08-29 2015-11-06 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in type 2 diabetes patients
AR087744A1 (en) 2011-09-01 2014-04-16 Sanofi Aventis Deutschland PHARMACEUTICAL COMPOSITION FOR USE IN THE TREATMENT OF A NEURODEGENERATIVE DISEASE
US9980669B2 (en) 2011-11-07 2018-05-29 Abbott Diabetes Care Inc. Analyte monitoring device and methods
WO2013158276A1 (en) 2012-04-20 2013-10-24 Children's Hospital Medical Center Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices
US9623179B2 (en) 2012-08-30 2017-04-18 Medtronic Minimed, Inc. Safeguarding techniques for a closed-loop insulin infusion system
US10496797B2 (en) 2012-08-30 2019-12-03 Medtronic Minimed, Inc. Blood glucose validation for a closed-loop operating mode of an insulin infusion system
US9849239B2 (en) 2012-08-30 2017-12-26 Medtronic Minimed, Inc. Generation and application of an insulin limit for a closed-loop operating mode of an insulin infusion system
US9878096B2 (en) 2012-08-30 2018-01-30 Medtronic Minimed, Inc. Generation of target glucose values for a closed-loop operating mode of an insulin infusion system
US9364609B2 (en) 2012-08-30 2016-06-14 Medtronic Minimed, Inc. Insulin on board compensation for a closed-loop insulin infusion system
US10130767B2 (en) 2012-08-30 2018-11-20 Medtronic Minimed, Inc. Sensor model supervisor for a closed-loop insulin infusion system
US9662445B2 (en) 2012-08-30 2017-05-30 Medtronic Minimed, Inc. Regulating entry into a closed-loop operating mode of an insulin infusion system
US9968306B2 (en) 2012-09-17 2018-05-15 Abbott Diabetes Care Inc. Methods and apparatuses for providing adverse condition notification with enhanced wireless communication range in analyte monitoring systems
KR102205512B1 (en) 2012-11-13 2021-01-20 아도시아 Quick-acting insulin formulation including a substituted anionic compound
CN104994864B (en) 2012-12-19 2018-05-29 沃克哈特有限公司 Include actrapid monotard or the stable aqueous composition of its analog or derivative
CA2889162A1 (en) 2012-12-26 2014-07-03 Wockhardt Limited Pharmaceutical composition
CA2909954C (en) 2013-04-28 2021-03-23 Impel Neuropharma, Inc. Medical unit dose container
MX389178B (en) 2014-12-12 2025-03-20 Sanofi Aventis Deutschland FIXED RATIO FORMULATION OF INSULIN GLARGINE/LIXISENATIDE.
HK1245116A1 (en) * 2015-02-25 2018-08-24 Dance Biopharm Inc. Liquid insulin formulations and methods relating thereto
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
CN108601916B (en) 2015-09-10 2021-07-09 英倍尔药业股份有限公司 In-line nasal delivery device
HRP20221324T1 (en) 2016-12-16 2022-12-23 Novo Nordisk A/S Insulin containing pharmaceutical compositions
EP4360651A3 (en) 2017-08-24 2024-07-17 Novo Nordisk A/S Glp-1 compositions and uses thereof
US11395887B2 (en) 2017-11-21 2022-07-26 Impel Pharmaceuticals Inc. Intranasal device with inlet interface
US11571532B2 (en) 2017-11-21 2023-02-07 Impel Pharmaceuticals Inc. Intranasal device with dip tube
RU2020125871A (en) 2018-01-05 2022-02-07 Импел Ньюрофарма, Инк. INTRANASAL DELIVERY OF DIHYDROERGOTAMINE USING A PRECISION DELIVERY DEVICE TO THE OLFACTORY REGION
BR112020013750A8 (en) 2018-01-05 2022-10-18 Impel Neuropharma Inc INTRANASAL DISPENSE OF OLANZAPINE BY PRECISION OLFATIVE DEVICE
KR20210034047A (en) 2018-07-19 2021-03-29 임펠 뉴로파마 인코포레이티드 Airway delivery of levodopa and dopa decarboxylase inhibitors for the treatment of Parkinson's disease
CN113473967B (en) 2019-01-03 2022-09-09 英倍尔制药公司 Transnasal drug delivery device
BR112021023049A8 (en) 2019-05-17 2022-10-18 Impel Neuropharma Inc SINGLE USE NASAL DISPENSING DEVICE
CA3165355A1 (en) 2020-02-18 2021-07-22 Tommy SANDER Pharmaceutical formulations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5767548A (en) * 1980-10-14 1982-04-24 Shionogi & Co Ltd Insulin analog and its preparation
US4839341A (en) * 1984-05-29 1989-06-13 Eli Lilly And Company Stabilized insulin formulations
GB9320782D0 (en) 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
US5474978A (en) 1994-06-16 1995-12-12 Eli Lilly And Company Insulin analog formulations
US5547929A (en) 1994-09-12 1996-08-20 Eli Lilly And Company Insulin analog formulations
EP0726075A1 (en) 1995-02-08 1996-08-14 Therapicon Srl Pharmaceutical non-inorganic saline solutions for endonasal administration
YU18596A (en) 1995-03-31 1998-07-10 Eli Lilly And Company Analogous formulations of monomer insulin
CO4750643A1 (en) 1997-06-13 1999-03-31 Lilly Co Eli STABLE FORMULATION OF INSULIN CONTAINING L-ARGININ AND PROTAMINE
CO4970787A1 (en) 1997-12-23 2000-11-07 Lilly Co Eli INSOLUBLE COMPOSITIONS OF INSULIN AND INSULIN DERIVATIVES THAT CONTROL BLOOD GLUCOSE
JP2002500196A (en) 1998-01-09 2002-01-08 ノヴォ ノルディスク アクティーゼルスカブ Stabilized insulin composition
EP1084245B1 (en) 1998-06-11 2006-03-29 AstraZeneca AB Human receptor tyrosine kinase

Also Published As

Publication number Publication date
WO2001052937A1 (en) 2001-07-26
US20010031726A1 (en) 2001-10-18
US6734162B2 (en) 2004-05-11

Similar Documents

Publication Publication Date Title
AU2001220765A1 (en) Mixed buffer system for stabilizing polypeptide formulations
AU2001236005A1 (en) Preparations stabilized over long time
AUPR022300A0 (en) Cement render system
AU2001294192A1 (en) Solid preparations
AU2001281096A1 (en) Bone anchoring system
EP1334724A4 (en) Compositions for external preparations
EP1032211A3 (en) Moving picture transcoding system
AU2001282607A1 (en) Solution preparations stabilized over long time
AU2001242020A1 (en) Imaging system
AUPP650198A0 (en) Cement formulation
AU6386801A (en) System for the release of active ingredients
AU2001284418A1 (en) Novel polypeptide
AU2001275409A1 (en) Methods and compositions for controlled polypeptide synthesis
AU2002232803A1 (en) Expression system for recombinant proteins
AU2002236588A1 (en) System for direct sequence spreading
AU2002232707A1 (en) Transmembrane proteins
AU2001286996A1 (en) Stabilized fgf formulations containing reducing agents
AU4352000A (en) Clasp-2 transmembrane proteins
AU2001296389A1 (en) Stable peptide formulations
AU3455000A (en) Composition for decomposing protein
AU2001281464A1 (en) Recombinant proteins containing repeating units
AU2001272427A1 (en) Solid preparations
AU2002239747A1 (en) Cystoskeleton-associated proteins
AU2001253548A1 (en) Video messaging system
AU2001236058A1 (en) Preparations for chondrogenesis